OACB News and Press, Oaktree Acquisition Corp. II Class A

Alvotech and SPAC Oaktree Acquisition Corp. II (NYSE:OACB) on Tuesday said that their planned merger was approved by OACB shareholders. OACB agreed to take Alvotech, a biopharmaceutical company developing biosimilars, public in Dec. 2021 at a $2.25B valuation. The merger is anticipated to clo...

Business Combination anticipated to close on or about June 15, 2022 Ordinary shares of Alvotech expected to trade under the new ticker symbol “ALVO” from June 16, 2022 on The Nasdaq Stock Market in New York and from June 23, 2022 on the Nasdaq First Nor...

Business Combination remains subject to satisfaction of customary closing conditions, including shareholder approval Oaktree Acquisition Corp. II (NYSE: OACB) (“OACB” or the “Company”) announced today that, assuming satisfaction of the conditions ...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara ® (ustekinumab) met its primary endpoint AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and biosimilar candidates, which includes AVT02 (ada...

- Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Alvotech Holdings S.A. (“Alvotech”), a global biotech company focused solely on the development and manufacture of biosimil...

Alvotech Holdings S.A. (“ Alvotech S.A. ”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition Corp. II (NYSE: OACB), a special purpose acquisition company sponsor...

Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company’s capital position and to replace any redeemed capital as part of their proposed merger Parties agree to reduce the minimum cash condition outlined in the merger agreement, t...

Upon launch, HUKYNDRA ® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market All intellectual-property disputes related to market entry of Alvotech’s AVT02 (adalimumab) in the U.S. and Europe are now resolved ...

Northland has initiated SPAC Oaktree Acquisition Corp. II (NYSE:OACB -0.3%) with an outperform rating ahead of its planned merger with Icelandic biotech Alvotech. The acquisition, announced in December, values Alvotech at $2.25B. Northland has a $15 price target (~51% upside based on Fri...